Neurotrophic keratopathy Phase III
In a randomised, placebo-controlled, double-masked Phase III trial of RGN-259 eye drops in people with Stage 2 or 3 neurotrophic keratopathy (a nerve-related corneal disease), complete healing at 4 weeks occurred in 6 of 10 treated subjects versus 1 of 8 given placebo. That difference gave p = 0.0656, which is above the usual 0.05 threshold. The authors also reported other significant healing measures and better eye comfort scores in the treated group, and no significant adverse effects.
- Study type
- Human trial
- Population
- Human, Stage 2 or 3 neurotrophic keratopathy, 18 subjects in the healing comparison (10 RGN-259, 8 placebo)
- Source
- 1 Sosne et al., 2022
Limitation: Very small trial.
Limitations in full
Very small trial. The headline 4-week complete-healing comparison did not reach the usual 0.05 threshold. Full-length thymosin beta-4 as eye drops, so it says nothing about TB-500. Read from the abstract record on Europe PMC; the abstract does not state which measure was the primary endpoint.